Medications which cause pancreatitis

To learn more about Healthwise, visit Healthwise. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.

Top of the page. Topic Overview In certain cases, medicines may cause inflammation of the pancreas pancreatitis. These include: Antibiotics. Medicines that suppress the immune system. Medicines used to treat high blood pressure. Medicines used to treat diabetes. The table below contains a summary of some of the most common drugs associated with acute pancreatitis in adults. Please note that this table does not contain all possible medications capable of being responsible for DIAP.

Pancreatitis is a rare side effect of these drugs in some individuals, and most individuals that take these drugs do not develop pancreatitis. Most individuals exposed to these drugs do not develop pancreatitis.

Conclusion DIAP is a rare cause of pancreatitis. Diagnosis of DIAP as the cause of acute pancreatitis is challenging and requires that other causes, such as gallstones or a pathogenic genetic variant be ruled out. As the drugs listed in this article demonstrate, there are multiple mechanisms through which medications can affect the body and lead to DIAP, although many of these mechanisms are not well understood.

If you suspect you may have experienced an acute pancreatitis attack, please speak to a healthcare professional to obtain the appropriate evaluation and treatment, if necessary. Risk of acute pancreatitis in users of azathioprine: a population-based case-control study. Am J Gastroenterol.

PMID: J Clin Gastroenterol. Simons-Linares, C. Campagnola, Pietro. Recurrent pantoprazole-associated pancreatitis. Am J Ther 25 4 :e—e Cancer Med 5 5 — Anticancer Res December 30 12 — Google Scholar.

J Pharmacol Pharmacother 7 1 — Clamon G Pancreatitis associated with newer classes of antineoplastic therapies. JCSO 15 3 :e—e Bajwa R, Cheema A, Khan T et al Adverse effects of immune checkpoint inhibitors programmed death-1 inhibitors and cytotoxic T-lymphocyte-associated protein-4 inhibitors : results of a retrospective study.

J Clin Med Res 11 4 — Hematol Transfus Cell Ther 40 4 — Krishnamurthy P, Brown M, Agrawal S, Short RF Acute pancreatitis as a complication of trans-arterial chemoembolization of hepatocellular cancer-case report and review of literature. J Gastrointest Oncol 8 1 :E26—E Clin Mol Hepatol 18 3 — European journal of hospital pharmacy ; A Dig Dis Sci — Braz J Infect Dis 18 4 — Download references.

All respect and indebtedness to the great professor Dr. Omkolsoum Alhaddad who created this work for her unlimited, sincere, and priceless inputs complying this work to be fulfilled. You can also search for this author in PubMed Google Scholar.

All authors have read and approved the manuscript. Correspondence to Maha Elsabaawy. Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material.

If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

Reprints and Permissions. Alhaddad, O. Updates in drug-induced acute pancreatitis. Egypt Liver Journal 10, 49 Download citation.

Received : 10 June Accepted : 12 October Published : 19 October Anyone you share the following link with will be able to read this content:. Sorry, a shareable link is not currently available for this article. Provided by the Springer Nature SharedIt content-sharing initiative.

Skip to main content. Search all SpringerOpen articles Search. Download PDF. Abstract Background Being infrequent, drug-induced acute pancreatitis DIP is an overlooked clinical entity that can be serious with significant morbidity and mortality.

Main body A renovative review of drugs incriminated in acute pancreatitis had been presented with all relevant data and case presentations. Conclusions DIP should be suspected as a potential adverse event to every newly emerged drug. Background Prevalence of DIP Drug-induced pancreatitis, a potentially forgotten diagnosis that should be rigorously appreciated. Table 1 Badalov classification system of drug-induced acute pancreatitis [ 5 ] Full size table. Review of potential offenders Propofol Propofol introduced itself to the market about three decades ago as a safer short-acting anesthetic agent.

Antibiotics Minocycline is a tetracycline while tigecycline is a glycylcycline and a structural derivative of minocycline [ 11 ]. Antidiabetic drugs In and in response to 30 post-marketing reports, FDA has ordered a warning label about a potential risk of acute pancreatitis in patients taking exenatide and sitagliptin, the first members of incretin-based therapies [ 18 ].

Antihypertensive agents Case reports of acute pancreatitis induced by enalapril, lisinopril, captopril, ramipril, and perindopril have been published. Acid-suppressing drugs In many case reports, cimetidine and ranitidine have been associated with acute pancreatitis.

Anticancer therapies Anticancer drugs almost always carry the risk of precipitation acute pancreatitis. The new direct-acting antiviral therapies DAAs of hepatitis C virus HCV DIP occurrence with the previously known combination of peginterferon and ribavirin had been substantiated [ 36 ]. Conclusion Literature has recently liberated several reports of case reports concerning DIP with an array of newly emerged drugs like propofol infusion, antidiabetics GLP1 agonists and DDP4 inhibitors, and SGLT2 inhibitors, particularly, canagliflozin , antibiotics minocycline , antihypertensive agents enalapril, lisinopril, captopril, ramipril, perindopril, and less frequently angiotensin receptor blockers , proton pump inhibitors omeprazole, pantoprazole, and lansoprazole , anticancer drugs nivolumab, pembrolizumab, ipilimumab , the newer TKIs vemurafenib and ponatinib , proteasome inhibitors bortezomib , and non-selective TACE, and direct-acting antiviral therapies DAAs of hepatitis C virus along with ribavirin.

Availability of data and materials Data used to support the findings of this study are included within the article.

References 1. Am J Ther 28 8. Cancer Med 5 5 — Article Google Scholar Anticancer Res December 30 12 — Google Scholar Acknowledgements All respect and indebtedness to the great professor Dr. Funding This review and the publication were completely funded by all authors. View author publications. Ethics declarations Ethics approval and consent to participate The review was conformed to the ethical guidelines of the Declaration of Helsinki and was approved by the institutional review board of the National Liver Institute NLI IRB , Menoufia University.

Consent for publication Not applicable for review article. Competing interests The authors declare that they have no competing interests.